Related Experiment Video
Updated: Jul 8, 2026
10:30
Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
Published on: May 24, 2016
Duchenne muscular dystrophy: an old anesthesia problem revisited.
Jason Hayes1, Francis Veyckemans, Bruno Bissonnette
1The Hospital for Sick Children, Toronto, ON, Canada. jason.hayes@sickkids.ca
Paediatric Anaesthesia
|January 11, 2008
Summary
Patients with muscular dystrophy are at risk for rhabdomyolysis during anesthesia. This review categorizes these perioperative reactions and offers guidance for safe anesthetic management in muscular dystrophy patients.
Area of Science:
- Anesthesiology
- Neuromuscular Disorders
- Genetics
Background:
- Duchenne and Becker muscular dystrophy result from dystrophin gene defects, causing progressive muscle deterioration.
- These patients face increased risks for perioperative complications, including rhabdomyolysis.
- Inhalational anesthetics may trigger acute rhabdomyolysis, mimicking malignant hyperthermia (MH).
Purpose of the Study:
- To review and categorize perioperative "MH-like" reactions in muscular dystrophy patients.
- To discuss the etiology and pathophysiology of these reactions.
- To propose recommendations for safe anesthetic management.
Main Methods:
- Literature review of reported perioperative "MH-like" reactions in muscular dystrophy patients.
- Categorization of reactions based on clinical presentation.
- Discussion of underlying pathophysiological mechanisms.
Main Results:
- Perioperative "MH-like" reactions in muscular dystrophy patients were identified and grouped into three clinical categories.
- The role of inhalational anesthetic agents in precipitating rhabdomyolysis was examined.
- Underlying pathophysiological processes were analyzed.
Conclusions:
- Muscular dystrophy patients are susceptible to "MH-like" rhabdomyolysis during anesthesia.
- Understanding these reactions is crucial for patient safety.
- Specific anesthetic management strategies are recommended to mitigate risks.
Related Concept Videos
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:19Depolarizing Blockers: Pharmocokinetics
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
01:21Skeletal Muscle Relaxants: Adverse Effects
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...